Pancreatic cancer is one of the most lethal malignancies due to its aggressive growth and rapid development of distant metastases. In this context, mucin 1 (MUC1) overexpression and hypoxia are frequently observed events. However, their functional relationship remains largely unknown. This study provides evidence that MUC1 is overexpressed by hypoxia and contributes to hypoxia-driven angiogenesis. Using the conditioned medium obtained from hypoxia-stressed AsPC1 cells treated with MUC1 siRNAs, we demonstrated that MUC1 enhanced the endothelial tube formation, proliferation and migration ability, which induced by hypoxia-conditioned medium (HCM). In addition, MUC1 was significantly induced by hypoxia, especially in the pancreatic cancer cells derived from metastatic tumors (AsPC1, HPAF2 or Capan1), and MUC1-cytoplasmic tail (MUC1-CT) accumulated in the nucleus under hypoxia. As noted in a previous report, MUC1-CT was recruited to genomic regions upstream of the connective tissue growth factor (CTGF) accompanied with b-catenin and p53, resulting in the hypoxic induction of CTGF. Moreover, hypoxiainduced MUC1 partially regulated two other hypoxia-inducible proangiogenic factors including vascular endothelial growth factor-A and platelet-derived growth factor-B. The neutralization assay revealed that endothelial tube formation induced by HCM was clearly suppressed by antibodies against these three factors, suggesting the importance of these factors in hypoxia-driven angiogenesis. In summary, this is the first report demonstrating a pivotal role of MUC1 in controlling the hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors in pancreatic cancer. Our findings provide the novel insights into the understanding of complex interactions between pancreatic cancer cells and tumor microenvironments.
INTRODUCTION
Pancreatic cancer is the most lethal malignancy, which is usually diagnosed at an advanced state for which there are few or no effective therapies. The incidence rates are nearly equal to the mortality rates in the industrial countries. 1 Surgical resection is the only potentially curative therapeutic approach. However, due to the lack of early symptoms, the vast majority of patients present with metastases, rendering their malignancies inoperable. Nearly all patients develop local recurrence and/or distant metastases even if the disease is diagnosed at an early stage and surgical resection is carried out. Clearly, there is a need for better biomarkers and the identification of new therapeutic targets, particularly for metastatic disease.
The extensive growth of solid tumors such including pancreatic cancer is often associated with defective tumor vascularization that cannot keep up with the overall oxygen need for the tissue, thus resulting in tumor hypoxia. [2] [3] [4] Rapidly growing tumors have to adapt to hypoxia through either angiogenesis to ensure an adequate oxygen supply and nutrients or metastasis to a more comfortable environment to sustain the cell growth and survival in their hostile microenvironment. Both clinical and laboratory evidence strongly suggests that hypoxia is associated with a poor prognosis and a predictive factor due to its multiple contributions to tumor development, growth, invasiveness, angiogenesis, other survival responses and resistance to therapy. [5] [6] [7] [8] The best characterized response pathway is mediated by hypoxia-inducible factors (HIFs), activating a vast array of gene products controlling survival, motility, energy metabolism, pH and neovascularization. 9 Mucin 1 (MUC1) is large membrane-bound glycoprotein that is translated as a single polypeptide, which undergoes an intracellular autocatalytic proteolytic cleavage into two subunits that form a stable non-covalent heterodimer and transport to the cell surface. 10, 11 The MUC1 N-terminal is large extracellular MUC subunit containing variable numbers of 20 amino-acid tandem repeats linked to hundreds of O-glycans. The MUC1 C-terminal is a transmembrane subunit composed of a short extracellular domain and a 72-amino-acid MUC1-cytoplasmic tail (MUC1-CT). Under physiological conditions, MUC1 is expressed on the apical borders of normal secretory epithelial cells and functions in providing a protective barrier of the epithelial cell surface. 12, 13 On the other hand, MUC1 is significantly overexpressed with malignant transformation, and aberrantly glycosylated in most cases of tumor types, including pancreatic ductal adenocarcinoma, and associated with a poor outcome. 14 Multiple studies revealed that MUC1 contributes to oncogenesis by promoting the loss of epithelial cell polarity, growth and survival pathways, receptor tyrosine kinase signaling pathways and resistance to the stressinduced cell death pathway. 15, 16 MUC1-CT interacts with several protein partners (such as b-catenin, p53, endoplasmic reticulum-a and signal transducer and activator of transcription) and transactivates a variety of target genes involved in the cancer progression.
Emerging evidence demonstrates that HIF1a directly activates MUC1 expression under hypoxia in lung and renal cell carcinoma. 18, 19 Recent studies using clinical samples also support that MUC1 expression is correlated with tumor hypoxia. 20, 21 However, the functional relationship between a hypoxic microenvironment and MUC1 is still largely unknown. Therefore, this study investigated the role of MUC1 in hypoxia-stressed pancreatic cancer cells and demonstrated the potential involvement of MUC1 in the hypoxia-driven angiogenesis.
RESULTS

MUC1
contributes to the endothelial cell tube formation induced by conditioned media from hypoxia-stressed pancreatic cancer cells The evidence suggests that tumor cells expressing high levels of MUC1 may have an increased invasive and metastatic potential, and also associated with intratumoral vascularization. 20, 22 Previous studies also show that MUC1 expression is correlated with angiogenesis in some tumors. 23, 24 Given the substantial correlation between hypoxia and tumor angiogenesis, we hypothesized that MUC1 may have some role in hypoxia-driven angiogenesis in pancreatic cancer. To investigate the role of MUC1 in hypoxiadriven angiogenesis, we first collected the conditioned media from hypoxia-stressed AsPC1 cells treated with or without MUC1 siRNA, and applying the in vitro tube formation assay using human umbilical vein endothelial cells (HUVECs). Consistent with the previous reports, hypoxia-conditioned media (HCM) showed high tube formation activity in comparison with that of normoxiaconditioned media. Interestingly, the activity of HUVEC tube formation of HCM from the cells treated with MUC1 siRNA was significantly attenuated in comparison with HCM treatment (Figure 1a ). In addition, MUC1 downregulation was associated with the suppression of HUVEC migration and proliferation ability induced by HCM (Figures 1b and c) , suggesting the potential involvement of MUC1 in the process of hypoxia-driven angiogenesis.
MUC1 is hypoxia responsive in pancreatic cancer cells derived from metastatic tumors and accumulated in the nucleus The AsPC1 cells were exposed to hypoxic culture conditions to examine the MUC1 expression in pancreatic cancer cells under hypoxic conditions. A western blotting analysis showed a significant increase of MUC1 using either MUC1-tandem repeat recognizing antibody (Ab) (HMPV) or MUC1-CT recognizing Abs (014E and Ab-5) with AsPC1 cells under hypoxia in a timedependent manner (Figure 2a) . Furthermore, the hypoxic induction of MUC1 was examined in several pancreatic cancer cell lines. HUVECs were grown to confluence on 24-well culture dishes and a single scratch was made in the confluent monolayer using a sterile pipette tip. The dish was washed with phosphate-buffered saline and conditioned media was added. The area of cells that had migrated over the margins of the wounds after 12-h incubation was measured by Image J software. (c) HUVECs were treated with each conditioned medium for the indicated time. Cell viability was determined by the WST-8 assay. Each bar represents the mean ± s.d. for three independent experiments. P-values were determined using the Student's t-test. *Po0.05; **Po0.005.
MUC1 regulates the hypoxia-driven connective tissue growth factor (CTGF) expression in pancreatic cancer cells Recently, Behrens et al. 25 reported that MUC1-CT directly regulates the expression of CTGF in pancreatic cancer. CTGF is a potent angiogenic factor induced by hypoxia in several cancers. 26, 27 Therefore, we hypothesized that hypoxia-induced MUC1 may regulate the CTGF expression under hypoxia. To examine whether CTGF is induced by hypoxia in pancreatic cancer, we first tested the CTGF induction under hypoxic exposure using AsPC1 and HPAF2 cells (Supplementary Figure S1) . The result showed that CTGF is hypoxia responsive in both cell types. The level of CTGF expression was examined in AsPC1 cells treated with MUC1 siRNA under hypoxia. Although there is no marked change in the expression of hypoxic markers, CAIX and HIF1a, the CTGF mRNA and protein levels under hypoxia were strongly suppressed by the knockdown of MUC1 ( Figure 3a and b and Supplementary Figure  S2 ). Furthermore, to examine the effect of MUC1 knockdown on the CTGF secretion from the AsPC1 cells, sandwich enzyme-linked immunosorbent assay was performed using conditioned media from the hypoxia-exposed AsPC1 cells treated with MUC1 siRNA, resulting in the suppression of CTGF secretion in comparison with HCM ( Figure 3c ).
MUC1-CT-and MUC1-associated proteins are localized to the CTGF promoter under hypoxia To explore the detailed mechanism of hypoxic induction of CTGF, we further examined the localization of hypoxia-induced MUC1-CT on CTGF promoter region ( À 2345/ À 1996), which reported as a recruiting site for MUC1-CT. 25 Chromatin immunoprecipitation (ChIP) studies demonstrated the increased occupancy of MUC1-CT at À 2345/ À 1996 upon the hypoxic exposure of AsPC1 cells. No change in occupancy in the distant region ( À 6659/ À 6514) was detected ( Figure 4a ). This study examined the localization of these proteins in hypoxia-stressed AsPC1 cells to investigate whether the hypoxia-induced MUC1-CT also influences the occupancy of either of MUC1-CT-associated transcription factors, p53 and b-catenin at the CTGF promoter. There was a substantial increase of p53 detected in the nucleus of hypoxia-stressed AsPC1 cells.
In contrast, there was no significant change in the constitutive expression of b-catenin (Figure 4b ). However, a ChIP assay showed that occupancy of both p53 and b-catenin were increased at À 2345/ À 1996 of the promoter region of CTGF in hypoxiastressed AsPC1 cells (Figure 4c ). Downregulation of MUC1 attenuates the hypoxia-driven vascular endothelial growth factor-A (VEGFA) and platelet-derived growth factor-B (PDGFB) in pancreatic cancer cells Several studies have also suggested that MUC1 regulates the expression of proangiogenic factors including VEGF and PDGF.
28-31 Therefore, we examined whether hypoxia-induced MUC1 is involved in the expression levels of other multiple angiogenic factors under hypoxia. By the quantitative real time PCR, we found that hypoxia-inducible VEGFA and PDGFB are partially suppressed in the AsPC1 cells by the treatment of MUC1 siRNA (Figure 5a ). The same result was also observed at the secretory protein levels of VEGFA and PDGFB in the culture media (Figure 5b ).
MUC1 contributes to endothelial cell tube formation through the regulation of hypoxia-driven proangiogenic factors To further investigate whether the MUC1-associated hypoxiadriven proangiogenic factors are really involved in the endothelial cell tube formation process, we performed the HUVEC tube formation assay using HCM with neutralizing Abs (Figure 6 ). The data showed that HUVEC tube formation-induced HCM was inhibited by each treatment with neutralizing Ab against CTGF, PDGFB and VEGFA, respectively. In particular, VEGF inhibition had the most potent anti-angiogenic effects on endothelial tube formation. In addition, HUVEC tube formation induced by HCM treatment in the presence of all three type of Abs was almost completely suppressed, suggesting the synergistic effects of these proangiogenic factors in this process. Given the MUC1 contributions to the hypoxic induction of three angiogenic factors, these data thus indicate that MUC1 could be a key modulator in controlling hypoxia-driven angiogenesis in pancreatic cancer. Role of MUC1 in hypoxia-driven angiogenesis S Kitamoto et al DISCUSSION It has been extensively reported that hypoxia induces the transcription of various genes involved in angiogenesis and anaerobic metabolism necessary for the survival and metastasis of tumor cells, suggesting a pivotal role of the hypoxic tumor microenvironment in cancer progression. Only two studies described a functional role of MUC1 under hypoxia. Aubert et al. 18 showed that MUC1 is induced by hypoxia in renal cell carcinomas through the HIF1a-mediating pathway and contributes to the invasive and migration properties of renal cancer cells. Yin et al. 32 demonstrated that MUC1 contributes to the inhibition of hypoxia-induced cell death by suppressing the accumulation of reactive oxygen species in colon and breast cancer. However, the functional role of MUC1 in hypoxia remains largely unknown. In this study, we found that MUC1 overexpression in hypoxia-stressed pancreatic cancer contributes to endothelial cell tube formation through the regulation of multiple hypoxia-driven proangiogenic factors including CTGF, VEGFA and PDGFB.
Angiogenesis in solid tumors is important for metastasis and consists of multiple processes including endothelial cell proliferation, migration and alignment to form capillary-like structures. This study used the conditioned medium obtained from hypoxiastressed AsPC1 cells treated with MUC1 siRNAs to demonstrate that MUC1 contributes to endothelial tube formation, proliferation and migration ability, induced by HCM. As observed in other type of solid tumors, 18, 19 MUC1 is also induced by hypoxia in pancreatic cancer cells. Furthermore, MUC1-CT was translocated to the nucleus in hypoxia-stressed cells. Interestingly, MUC1 is likely to be more hypoxia responsive in pancreatic cancer cells derived from metastatic tumors in comparison with those from primary tumors, indicating the involvement of MUC1 in the hypoxia-related tumor metastatic properties.
As a molecular determinant behind the hypoxia-driven angiogenesis shown in Figure 1 , we first identified that CTGF is a proangiogenic factor regulated by MUC1 under hypoxia. CTGF is a multifunctional growth factor in wound repair, inflammation, cell adhesion, apoptosis, tumor growth, and fibrotic disorders and overexpressed in a wide variety of cancers. 33 A neutralizing CTGFspecific monoclonal Ab strongly attenuates both anchorageindependent growth of pancreatic cancer cells in vitro as well as primary and lymph node metastasis in vivo, suggesting the importance of CTGF as a potential therapeutic target. 34 CTGF colocalizes with hypoxic regions in human tumor xenografts as well as clinical pancreatic adenocarcinoma specimens. 26 In this context, Higgins et al. 35 reported that CTGF is a direct transcriptional target of HIF1a, which interacts with HREs located in the promoter. However, the exact mechanism of CTGF under hypoxia remains controversial. In this regard, our data showed that MUC1 knockdown under hypoxia resulted in the almost complete suppression of hypoxic CTGF induction in contrast to no effect on the hypoxic induction of CAIX, a marker for HIF1a activity. We also detected that neither hypoxic exposure nor the knockdown of MUC1 did influence the expression level of transforming growth factor-b, known as a potent inducer of CTGF, suggesting the limited role of transforming growth factor-b in hypoxic induction of CTGF (data not shown). These findings indicate that the MUC1-mediating pathway may exist in the Conditined media were collected as described in the Materials and methods section. CTGF secretion level was monitored by enzyme-linked immunosorbent assay. Each bar represents the mean±s.d. for at least three independent experiments. P-values were determined using the Student's t-test. *Po0.05.
Role of MUC1 in hypoxia-driven angiogenesis S Kitamoto et al regulation of hypoxic induction of CTGF and provides a new insight into the complex regulatory mechanism of CTGF in cancer progression.
Moreover, this study also identified that hypoxia-induced MUC1 partially contributes to upregulation of VEGFA and PDGFB under hypoxia. Although the underlying mechanisms behind these phenomena remains unclear, it has been reported that MUC1 promotes the synthesis and secretion of VEGF through the AKT signaling pathway 30, 31 and is indeed crucial for the VEGF expression level and invasiveness of pancreatic cancer in vivo. 36 In addition, the recent study by Sahraei et al. 28 showed that MUC1 is associated with HIF1a and facilitates its translocation to the nucleus in pancreatic cancer cells, indicating the importance of MUC1 in the regulation of hypoxia-related genes including VEGFA and PDGFB. Papadopoulos et al. 24 showed that PDGFB also stimulates nuclear colocalization of MUC1-CT and b-catenin in pancreatic cancer and enhances tumor growth and metastases in vivo. These findings raise the possibility that hypoxia-inducible MUC1 may have a key role in the feedforward loop of hypoxiadriven angiogenesis.
As studies reported that hypoxia could stimulate the expression of several proangiogenic factors such including PDGFA, sonic hedgehog, transforming growth factor-b and hepatocyte growth factor activator, we also investigated the effect of MUC1 knockdown under hypoxia on the expression of these molecules. However, little or no change was observed in the mRNA levels (data not shown). Given the result of Ab neutralization assay demonstrated in Figure 6 , CTGF, PDGF and VEGF have synergistic and central role in hypoxia-driven angiogenesis in this model. However, downregulation of MUC1 was still insufficient to suppress the endothelial tube formation induced by HCM as comparison with that of mixed Abs treatment, suggesting that another pathway in addition to MUC1 exists in the regulation of hypoxia-driven angiogenesis. Taken together, the findings presented here show that hypoxia-inducible MUC1 contributes to hypoxia-driven angiogenesis through the activation of proangiogenic factors such as CTGF, PDGF and VEGF in pancreatic cancer. Although additional studies are needed, these findings may pave the way for achieving an improved molecular understanding of the complex interactions between pancreatic cancer cells and the tumor microenvironments.
MATERIALS AND METHODS
Cells and culture conditions
Human pancreatic carcinoma cell lines MiaPaca2, Panc1, BxPC3, AsPC1, HPAF2 and Capan1 were purchased from the American Type Culture Collection (Manassas, VA, USA). MiaPaca2 and Panc1 cells were maintained in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA); BxPC3 and AsPC-1 cells were maintained in RPMI-1640 medium (Sigma); HPAF2 cells were maintained in Eagle's minimum essential medium (Sigma); Capan1 cells were maintained in Dulbecco's modified Eagle's medium/F-12 (Sigma). All media were supplemented with 10% fetal bovine serum (Gibco, Breda, The Netherlands) and 100 U/ml penicillin/100 mg/ml streptomycin (Sigma). Human pancreatic ductal epithelium cells were a generous gift from Dr Ming-Sound Tsao (University of Toronto, Ontario, Canada) and maintained in Keratinocyte serum-free medium (Gibco) with 50 mg/ml bovine pituitary extract, 5 ng/ml epidermal growth factor. 37, 38 HUVECs were maintained in endothelial basal medium-2 media supplemented with BulletKit according to the supplier's instructions (Lonza, Walkersville, MD, USA). HUVECs between third and seventh passage were used for the experiments. Hypoxic culture conditions were achieved with a multi-gas incubator containing a gas mixture composed of 94% N 2 , 5% CO 2 and 1% O 2 (ASTEC, Fukuoka, Japan). Role of MUC1 in hypoxia-driven angiogenesis S Kitamoto et al
Preparation of the conditioned media
AsPC1 cells were cultured in serum-free Advanced RPMI-1640 (Gibco) supplemented with 2 mM L-glutamine and antibiotics, to prepare the conditioned media. The cells were incubated 48 h under normoxia or hypoxia, and the conditioned media of pancreatic cancer cells were harvested, centrifuged at 2000 g for 10 min, filtered through 0.22-mm filters and stored as normoxia-conditioned media or hypoxia-conditioned media (HCM). Each conditioned medium was concentrated by 10-fold through 3000 molecular weight cutoff filters (Vivaspin, GE Healthcare, Uppsala, Sweden) according to the manufacturer's instruction and stored at À 80 1C until use for the wound healing assay, cell growth assay and in vitro angiogenesis assay.
RNA interference
MUC1 knockdown was performed using On-Target plus siRNA (Dharmacon, Boulder, CO, USA) according to the manufacturer's instruction. OnTarget plus siControl nontargeting siRNA was used as a control. Briefly, AsPC1 cells were seeded in 6-cm dishes and at 50% confluence were transfected with 13.6 nmol/l siRNA using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). After 12-h incubation, the medium was refreshed and the cells were incubated for indicated times under hypoxic condition.
RNA extraction and real time reverse transcription-PCR
Total RNA was extracted from the cells using the RNeasy mini kit (Qiagen, Hilden, Germany) and quantified by NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Montchanin, DE, USA). . MUC1 contributes to endothelial cell tube formation through the regulation of hypoxia-driven proangiogenic factors. AsPC1 cells were transfected with or without MUC1-siRNA. After the 48-h incubation under hypoxia, conditioned media for in vitro angiogenesis were prepared as described in the Materials and methods section. Then, HUVECs were trypsinized and seeded in each well containing 100 ml of each conditioned medium in the absence or presence of neutralizing Abs against CTGF, VEGF and PDGF. The total tube length was determined and shown as the percentage in comparison with that obtained with HCM treatment. Each bar represents the mean ± s.d. for three independent experiments. P-values were determined using the Student's t-test. *Po0.05; **Po0.005; NS, not significant.
GGTGGACGAT-3 0 . Real-time reverse transcription-PCR was performed on a ABI PRISM 7000 Sequence Detection System using the SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Gene expression was normalized to the b-actin mRNA level in each sample.
Protein extraction and western blotting
The cells were cultured on 6-cm dishes under hypoxia for the indicated time. Total cell lysates were prepared using RIPA buffer containing protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). The Universal Magnetic Co-IP kit (Active Motif, Carlsbad, CA, USA) was used for preparation of subcellular fractionation. Protein was measured by the bicinchoninic acid assay (Thermo Scientific, Rockford, IL, USA), equal amounts were resolved by 3-8% SDS-polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene difluoride membrane. The membranes were blocked with 1% skim milk/PBST (PBS with 0.1% Tween 20) over 1 h and subjected to the standard immunodetection procedure using specific primary Abs. The primary Abs were as follows: anti-human MUC1 (HMPV, 1:1000, BD Pharmingen, San Diego, CA, USA), anti-human MUC1-CT (Ab-5, 1:1000, Thermo Scientific), anti-human MUC1-CT (014E, 1:1000, generated in our laboratory 39 ), anti-human HIF1a (H1alpha67, 1:1000, Novus Biologicals, Littleton, CO, USA), anti-human CAIX (M75, 1:500, kindly provided by Dr Egbert Oosterwijk), anti-human Lamin B (C-20, 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-human atubulin (DM1A, 1:2000, Sigma).
Chromatin immunoprecipitation
The ChIP assay was performed using a ChIP-IT Express Enzymatic kit (Active Motif) as described previously. 40 Briefly, AsPC1 cells were grown to subconfluence in 15-cm dishes for 24 h under hypoxia. Protein/ chromatin was crosslinked with 3.7% formaldehyde for 10 min at room temperature. The crosslinking was quenched by adding 10 mM glycine/ phosphate-buffered saline solution for 5 min. Subsequently, cells were homogenized in an ice-cold Dounce homogenizer, and nuclei were collected by gently centrifugation. After suspending the nuclei with shearing buffer, the nucleoprotein complexes were sheared to fragments of 200-800 bp using the enzymatic shearing cocktail provided in the kit for 13 min. A 60-ml aliquot of sheared chromatin was used for each immunoprecipitation with 2 mg of MUC1-CT Ab (Ab-5, Thermo Scientific), p53 Abs (DO7, Abcam, Cambridge, MA, USA), b-catenin Abs (14/BetaCatenin, BD Transduction Laboratories, San Jose, CA, USA) or control immunoglobulin G. The ChIP primers were cited from the previously published paper. 25 
Sandwich enzyme-linked immunosorbent assay
The levels of CTGF, VEGFA and PDGFB in each conditioned medium from AsPC1 were determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions (Peprotech, London, UK).
Cell growth assay
Cell growth was examined by a colorimetric assay using WST-8 (Cell Counting Kit 8, Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. HUVECs (5 Â 10 3 cells/well) in 96-well plates were incubated at 37 1C for 1 h. The culture media were removed, and 100 ml of concentrated conditioned medium was pipetted into each well, followed by the additional incubation for the indicated time. The WST-8 assay was carried out in duplicate in three independent experiments.
Wound healing assay
HUVECs (2 Â 10 4 cells/well) were cultured in 24-well culture plates. A cellfree area was introduced by scratching confluent human mammary epithelial cells with a pipette tip. The cells were washed with phosphatebuffered saline, and 200 ml of concentrated culture medium was added into each well. The cells that migrated into the wound site after 12-h incubation were photographed and quantified using the Image J software program (National Institute of Health, Bethesda, MD, USA).
Tube formation assay
Angiogenesis was assessed using the in vitro angiogenesis assay kit (Cayman Chemical, Ann Arbor, MI, USA). Briefly, each well of pre-chilled 96-well cell culture plates was coated with a thin layer of the extracellular matrix gel (40 ml/well), which was left at 37 1C for 1 h to allow the gel to solidify. HUVECs were trypsinized and seeded (1 Â 10 4 cells/well) in each well containing 100 ml of conditioned medium from wild-type, MUC1 siRNA or control siRNA-transfected AsPC1 cells in the absence or presence of neutralizing Abs including anti-CTGF Abs (2 mg/ml, Peprotech), anti-VEGF Abs (4 mg/ml, Santa Cruz Biotechnology), anti-PDGF Abs (2 mg/ml, R&D Systems, Minneapolis, MN, USA) and control immunoglobulin G (anti a-tubulin monoclonal Abs, 4 mg/ml, Sigma). The cells were incubated for 24 h, stained with calcein AM, and capillary tube formation was assessed by counting five random fields/sample under a fluorescence microscope. The assessment of tube length and branch points in each of the entire field was calculated using the Image J analysis program.
Statistical analysis
All experiments were carried out at least three times unless otherwise noted. Data were expressed as the mean ± s.d. Two-sided Student's t-test was used for comparisons of the two different groups. Differences between groups were considered to be significant at Po0.05.
